Nordic Nanovector: Betalutin™ granted Orphan Designation in Europe

Oslo Cancer Cluster member Nordic Nanovector`s  lead product candidate Betalutin™ has been granted orphan designation for treatment of follicular lymphoma in Europe by the European Medicines Agency (EMA) and the European Commission (EC). Orphan designation for Betalutin™ will provide the company several advantages, including reduced costs related to the clinical development program, as well as […]

Nordic Nanovector: Betalutin™ granted Orphan Designation in Europe

Oslo Cancer Cluster member Nordic Nanovector`s  lead product candidate Betalutin™ has been granted orphan designation for treatment of follicular lymphoma in Europe by the European Medicines Agency (EMA) and the European Commission (EC). Orphan designation for Betalutin™ will provide the company several advantages, including reduced costs related to the clinical development program, as well as […]

Cambridge-report shows high number of oncology publications per capita in Norway

MBA students from University of Cambridge did a benchmarking of international oncology clusters this spring on behalf of the Oslo Cancer Cluster. Please download an excerpt of the report here. Key findings; • Norway has a high number of oncology publications per capita • The entrepreneurial culture in Norway represents untapped commercial potential • There […]

Cambridge-report shows high number of oncology publications per capita in Norway

MBA students from University of Cambridge did a benchmarking of international oncology clusters this spring on behalf of the Oslo Cancer Cluster. Please download an excerpt of the report here. Key findings; • Norway has a high number of oncology publications per capita • The entrepreneurial culture in Norway represents untapped commercial potential • There […]

Targovax successfully completes a 70 MNOK financing

Immunotherapy specialist Targovax announces completion of a 70 MNOK financing, mainly from new investors. The share issue was significantly oversubscribed. CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to […]

Targovax successfully completes a 70 MNOK financing

Immunotherapy specialist Targovax announces completion of a 70 MNOK financing, mainly from new investors. The share issue was significantly oversubscribed. CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to […]